Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat neurologically mediated conditions. The Company is engaged in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID), in patients with Parkinson’s disease. The Company is conducting a Phase 2b/3 clinical trial of nalbuphine ER. The Company has also commenced a Phase 1b clinical trial in patients with chronic liver disease to evaluate the safety, pharmacokinetics and anti-pruritic effect of nalbuphine ER in this population. The Company’s nalbuphine ER development programs are Chronic Pruritus Programs, Prurigo Nodularis Program, Pruritus in Chronic Liver Disease Program and Uremic Pruritus Program.